MeiTangMD

Oncology • Baltimore, MD

Physician

Join to view full profile

Dr. Tang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Tang's full profile

Already have an account?

Office
6569 N Charles St Ste 201
Baltimore, MD 21204
Phone+1 443-849-3051

Fax+1 443-849-3057
Is this information wrong?

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 2006 - 2009
Greater Baltimore Medical CenterResidency, Internal Medicine, 2003 - 2006
Shanghai Medical UniversityClass of 1992

Certifications & Licensure

MD State Medical License 2009 - 2025

Clinical Trials

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

46 citations
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Benjamin C. Creelan, Tammie C. Yeh, Sang We Kim, Naoyuki Nogami, Dong Wan Kim, Laura Q.M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angel...> ;British Journal of Cancer. 2021 Jan 19
18 citations
Establishing a Multidisciplinary Head and Neck Clinical Pathway: An Implementation Evaluation and Audit of Dysphagia-Related Services and Outcomes
Barbara Messing, Elizabeth C. Ward, Cathy L. Lazarus, Keri Ryniak, Melissa Kim, Jessica Silinonte, Dorothy Gold, Carol B. Thompson, Karen T. Pitman, Ray G. Blanco, Rya...> ;Dysphagia. 2019 Feb 1
2 citations
Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma.
Joseph A. Califano, Zubair Khan, Kimberly A. Noonan, Lakshmi Rudraraju, Zhe Zhang, Hao Wang, Steven D. Goodman, Christine G. Gourin, Patrick K. Ha, Carole Fakhry, John...> ;Clinical Cancer Research. 2018 Dec 1
32 citations
Neutrophil-to-lymphocyte ratio: Prognostic indicator for head and neck squamous cell carcinoma.
Nicholas J. Rosculet, Xian Chong Zhou, Patrick K. Ha, Mei Tang, Marshall A. Levine, Geoffrey Neuner, Joseph A. Califano> ;Head & Neck. 2017 Apr 1
138 citations
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma
Joseph A. Califano, Zubair Khan, Kimberly A. Noonan, Lakshmi Rudraraju, Zhe Zhang, Hao Wang, Steven D. Goodman, Christine G. Gourin, Patrick K. Ha, Carole Fakhry, John...> ;Clinical Cancer Research. 2015 Jan 1
35 citations
Pharyngocutaneous fistula after total laryngectomy: a single-institution experience, 2001-2012.
Eleni M. Benson, Richard M. Hirata, Carol B. Thompson, Patrick K. Ha, Carole Fakhry, John R. Saunders, Joseph A. Califano, Demetri Arnaoutakis, Marshall A. Levine, Mei...> ;American Journal of Otolaryngology. 2015 Jan 1
2 citations
Multidisciplinary service utilization pattern by advanced head and neck cancer patients: a single institution study.
Jacqueline C. Junn, Irene A. Kim, Marianna Zahurak, Marietta Tan, Katherine Y. Fan, Spencer Lake, David Zaboli, Barbara Messing, Karen Ulmer, Karen Harrer, Dorothy Gol...> ;International Journal of Otolaryngology. 2012 Oct 18
Human embryonic stem cell encapsulation in alginate microbeads in macroporous calcium phosphate cement for bone tissue engineering.
Tang, M.,Chen, W.,Weir, M. D.,Thein-Han, W.,Xu, H. H.> ;Acta Biomater. 2012 May 29
6 citations
The effect of amifostine on submandibular gland histology after radiation.
Jacqueline C. Junn, James J. Sciubba, Justin A. Bishop, Eva S. Zinreich, Mei Tang, Marshall A. Levine, Robert A. Palermo, Carole Fakhry, Ray G. Blanco, John R. Saunder...> ;International Journal of Otolaryngology. 2012 Jul 15
6 citations
Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients.
David Zaboli, Marietta Tan, Hrishikesh Gogineni, Spencer Lake, Katherine Y. Fan, Marianna Zahurak, Barbara Messing, Karen Ulmer, Eva S. Zinreich, Marshall A. Levine, M...> ;International Journal of Otolaryngology. 2012 Jun 21
12 citations
Comparison of Acute Toxicities in Two Primary Chemoradiation Regimens in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma
Katherine Y. Fan, Hrishikesh Gogineni, David Zaboli, Spencer Lake, Marianna Zahurak, Simon R. Best, Marshall A. Levine, Mei Tang, Eva S. Zinreich, John R. Saunders, Jo...> ;Annals of Surgical Oncology. 2012 Jan 31
88 citations
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters ...
Robert B. Nussenblatt, Darby J. S. Thompson, Zhuqing Li, Jan S. Peterson, Randy R. Robinson, Richard S. Shames, Sudha Nagarajan, Meina Tao Tang, Michelle Mailman, Gise...> ;Journal of Autoimmunity. 2003 Nov 1
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients ...
Sheridan, J. P., Zhang, Y., Riester, K., Tang, M. T., Efros, L., Shi, J., Harris, J., Vexler, V., Elkins, J. S.> ;Mult Scler. 2011 Dec
An engineered human IgG1 antibody with longer serum half-life.
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., Tsurushita, N.> ;J Immunol. 2006 Jan 1
Engineered human IgG antibodies with longer serum half-lives in primates.
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., Tsurushita, N.> ;J Biol Chem. 2004 Feb 20
Join now to see all